Biogen BIIB recently announced that the FDA has granted Breakthrough Therapy designation to Salanersen, an investigational next-generation antisense oligonucleotide (ASO) for the treatment of patients with spinal muscular atrophy (SMA).
The FDA’s Breakthrough Therapy designation is intended to facilitate drug development and expedite the review of therapies for serious diseases with unmet medical needs.
Breakthrough Therapy Tag Based on BIIB’s Phase Ib Data
The FDA's Breakthrough Therapy Designation for salanersen was supported by data from the phase Ib study in children with SMA who had an inadequate response to prior gene therapy. The study demonstrated that treatment with once-yearly dosing of salanersen led to meaningful improvements in motor function, reduced neurodegeneration as measured by lower neurofilament levels and a favorable safety profile.
SMA is a rare genetic neuromuscular disorder caused by insufficient production of the survival motor neuron (SMN) protein, leading to the progressive loss of motor neurons in the spinal cord. It represents one of the leading genetic causes of infant mortality and can result in varying degrees of disability in adolescents and adults.
Biogen currently markets Spinraza, the first FDA-approved treatment for SMA. Salanersen and Spinraza are ASOs designed to increase SMN protein production by modifying SMN2 gene splicing. However, Salanersen has several potential advantages. The biggest differentiator is dosing frequency. Spinraza requires four loading doses followed by maintenance doses every four months, while Salanersen has been engineered for enhanced potency, which may allow once-yearly administration, significantly reducing the treatment burden for patients.
The FDA approved a higher dose of Spinraza in March, which offers two initial doses spaced 14 days apart, followed by a maintenance dose every four months. However, the dosing regimen has not yet been launched.
Year to date, shares of Biogen have risen 11.7% against the industry’s 3.4% decline.
Image Source: Zacks Investment Research
More on Biogen’s Salanersen
Biogen acquired worldwide rights to develop, manufacture and commercialize Salanersen from Ionis Pharmaceuticals IONS in January 2022. The candidate was originally discovered by IONS.
Salanersen is being studied in a broad global phase III program comprising three studies: STELLAR-1, SOLAR and STELLAR-2.
STELLAR-1 is assessing salanersen in treatment-naïve, presymptomatic infants younger than six weeks with a genetic diagnosis of SMA.
SOLAR is evaluating the therapy in adolescents and adults aged 15 to 60 years with SMA, including both treatment-naïve patients and those previously treated with Evrysdi (risdiplam), Roche's RHHBY approved SMA therapy.
Meanwhile, STELLAR-2 will study salanersen in presymptomatic infants who received Zolgensma (onasemnogene abeparvovec-xioi) gene therapy at six weeks of age or younger, with Salanersen treatment initiated approximately six months later. The study is expected to begin this month. Zolgensma is a one-time gene replacement therapy developed by Novartis NVS.
BIIB’s Zacks Rank
Biogen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).